Kwetina

Quetiapine, the active ingredient in Kwetina, is a atypical antipsychotic presented as an oral tablet for oral use. It treats schizophrenia, bipolar disorder (both manic and depressive episodes) and is used as adjunctive therapy for major depressive disorder in adults.

GNH USA supplies Kwetina as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Quetiapine is an atypical antipsychotic that modulates neurotransmitter activity in several psychiatric disorders. - Schizophrenia: reduces psychotic symptoms such as hallucinations and delusions. - Bipolar disorder (manic episodes): stabilizes mood and diminishes manic symptoms. - Bipolar disorder (depressive episodes): alleviates depressive symptoms. - Adjunctive treatment of major depressive disorder: enhances the response to antidepressants.

Quetiapine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Dizziness - Somnolence - Dry mouth - Constipation - Weight gain - Orthostatic hypotension

Serious or Rare Side Effects: - Agranulocytosis - Neuroleptic malignant syndrome - Tardive dyskinesia - Severe hypotension - Suicidal thoughts or behaviors - Myocarditis or pericarditis

Before initiating therapy, clinicians should consider several safety aspects. - Cardiovascular assessment: monitor blood pressure and heart rate, especially in patients with pre‑existing hypertension. - Hepatic function: evaluate liver enzymes and adjust dose in severe impairment. - Psychiatric history: watch for worsening depression or emergent suicidality. - Age considerations: start low and titrate cautiously in elderly patients. - Discontinuation: avoid abrupt cessation; taper under medical supervision. - Store at ambient temperature: keep in the original pack, protect from moisture and light.

Quetiapine interacts with several drug classes that may require dose adjustment or avoidance.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase quetiapine plasma levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce therapeutic effect. - CNS depressants (alcohol, benzodiazepines): additive sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs): potential for serotonin syndrome. - Other antipsychotics (haloperidol): increased risk of QT prolongation. - Antihypertensives: may cause excessive hypotension.